Hepatectomy in patients with inherited blood coagulation disorders can be safely performed with adequate coagulation factor replacement.

Abstract

Haemophilia and von Willebrand disease (VWD) are common inherited bleeding disorders. Although patients with haemophilia or VWD have a high risk of hepatitis virus infection and hepatocellular carcinoma (HCC), little is known about the safety of liver resection in these patients. From 2006 to 2016, there were seven hepatectomies with haemophilia A and three hepatectomies with VWD for malignant liver tumours at tertiary care hospitals in Japan and Switzerland. To evaluate the safety of hepatectomy in the blood coagulation disorder group (BD group), short-term outcomes in these patients were compared with 20 hepatectomies (non-BD group) for HCC, matched to a 2:1, operative procedure, period and background liver. Ten liver resections were performed in patients with haemophilia or VWD with administration of recombinant FVIII or VWF concentrate. Comparison of the BD vs non-BD group revealed no significant differences in the operative time (327 vs 407minutes, P=0.359), estimated blood loss (730 vs 820mL, P=0.748), red blood cell transfusion rate (10.0% vs 5.0%, P=0.605), major complication rate (Clavien-Dindo grade III or IV) (10.0% vs 5.0%, P=0.605) or mortality rate (0% vs 0%, P>0.999). Additionally, the length of the postoperative hospital stay was similar between the two groups (13 vs 14days, P=0.296). Liver resection for treatment of HCC in patients with haemophilia or VWD can be safely performed through an appropriate perioperative administration protocol of coagulation factors.